Drug Treatment for Obesity. We Need More Studies in Men at Higher Risk of Coronary Events

Overview

Journal BMJ

Specialty General Medicine

Date 2001 Jun 9

PMID 11397730

Citations 4

Authors

J P Despres

Affiliations

Soon will be listed here.

Citing Articles

Adiponectin: An Indicator for Metabolic Syndrome.

Yosaee S, Khodadost M, Esteghamati A, Speakman J, Djafarian K, Bitarafan V Iran J Public Health. 2019; 48(6):1106-1115.

PMID: 31341853 PMC: 6635323.

CB1 antagonists for obesity--what lessons have we learned from rimonabant?.

Di Marzo V, Despres J Nat Rev Endocrinol. 2009; 5(11):633-8.

PMID: 19844251 DOI: 10.1038/nrendo.2009.197.

Adult obesity and growth in childhood.

Law C BMJ. 2001; 323(7325):1320-1.

PMID: 11739206 PMC: 1121795. DOI: 10.1136/bmj.323.7325.1320.

Drugs are not best for obesity.

Berry E BMJ. 2001; 323(7312):576.

PMID: 11573499 PMC: 1121151. DOI: 10.1136/bmj.323.7312.576.

References

Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P . International trial of long-term dexfenfluramine in obesity. Lancet. 1989; 2(8672):1142-5. DOI: 10.1016/s0140-6736(89)91499-2. View

Chapman M, Bruckert E . The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis. 1996; 124 Suppl:S21-8. DOI: 10.1016/0021-9150(96)05853-4. View

Tchernof A, Lamarche B, Prudhomme D, Nadeau A, Moorjani S, Labrie F . The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 1996; 19(6):629-37. DOI: 10.2337/diacare.19.6.629. View

Reaven G, Lithell H, Landsberg L . Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334(6):374-81. DOI: 10.1056/NEJM199602083340607. View

Reisin E, Abel R, Modan M, Silverberg D, ELIAHOU H, Modan B . Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978; 298(1):1-6. DOI: 10.1056/NEJM197801052980101. View

Despres J, Lemieux I, Prudhomme D . Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001; 322(7288):716-20. PMC: 1119905. DOI: 10.1136/bmj.322.7288.716. View

James W, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S . Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2001; 356(9248):2119-25. DOI: 10.1016/s0140-6736(00)03491-7. View

Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

Bray G, Blackburn G, Ferguson J, Greenway F, Jain A, Mendel C . Sibutramine produces dose-related weight loss. Obes Res. 1999; 7(2):189-98. DOI: 10.1002/j.1550-8528.1999.tb00701.x. View

10.

CASTELLI W . Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984; 76(2A):4-12. DOI: 10.1016/0002-9343(84)90952-5. View

11.

Weintraub M, SUNDARESAN P, Madan M, Schuster B, Balder A, Lasagna L . Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992; 51(5):586-94. DOI: 10.1038/clpt.1992.69. View